New arbitration full of upsides for Genmab, says analyst

Sydbank Senior Analyst Søren Løntoft Hansen says that there are many upsides and few downsides to Genmab’s decision to initiate new arbitration against Janssen.

Photo: Tuala Hjarnø / Genmab / PR

After losing a royalties case against its partner Janssen Biotech in April, Genmab has commenced new arbitration concerning Darzalex Faspro.

Genmab is seeking USD 405m plus interest on accrued milestone payments for Darzalex Faspro, as well as a new 13-year royalties contract backdated to the first commercial sale of the drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs